These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38173371)

  • 21. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy.
    Rhee MY; Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HY; Kim HS
    Clin Ther; 2019 Dec; 41(12):2571-2592. PubMed ID: 31727361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
    Park IR; Moon JS
    Diabetes Metab J; 2024 May; 48(3):387-389. PubMed ID: 38802118
    [No Abstract]   [Full Text] [Related]  

  • 23. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
    Kang Y; Park JM; Lee SH
    Yonsei Med J; 2024 Jan; 65(1):19-26. PubMed ID: 38154476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.
    Lee CJ; Kang WC; Ihm SH; Sohn IS; Woo JS; Kim JW; Hong SJ; Choi JH; Suh JW; Seo JB; Doh JH; Son JW; Park JH; Lee JH; Hong YJ; Heo JH; Shin J; Kang SM
    J Clin Hypertens (Greenwich); 2024 Mar; 26(3):262-273. PubMed ID: 38319595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy.
    Perez de Isla L; Liberopoulos E; Dovizio M; Veronesi C; Degli Esposti L; Zambon A
    Adv Ther; 2024 Aug; 41(8):3407-3418. PubMed ID: 38963586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.
    Olszewska-Banaszczyk M; Jackowska P; Gorzelak-Pabiś P; Pytel E; Koter-Michalak M; Broncel M
    Pharmacol Rep; 2018 Apr; 70(2):258-262. PubMed ID: 29475008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
    Cha JJ; Hong SJ; Kim JH; Lim S; Joo HJ; Park JH; Yu CW; Lee PH; Lee SW; Lee CW; Moon JY; Lee JY; Kim JS; Park JS; Lee K; Lim SY; Na JO; Cho JM; Kim SY; Lim DS
    Am Heart J; 2023 Jul; 261():45-50. PubMed ID: 36934981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fixed-dose combination of rosuvastatin and ezetimibe].
    Šatný M
    Vnitr Lek; 2020; 66(8):513-517. PubMed ID: 33740852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells.
    Woźniak E; Broncel M; Niedzielski M; Woźniak A; Gorzelak-Pabiś P
    PLoS One; 2023; 18(2):e0280741. PubMed ID: 36753488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia.
    Kim W; Yoon YE; Shin SH; Bae JW; Hong BK; Hong SJ; Sung KC; Han SH; Kim W; Rhee MY; Kim SH; Lee SE; Hyon MS; Hwang GS; Son JW; Kim JY; Kim MK; Kim SW; Park JH; Shin JH; Park CG
    Clin Ther; 2018 Jun; 40(6):993-1013. PubMed ID: 29857919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol.
    Ju SH; Ku BJ
    Medicine (Baltimore); 2022 Nov; 101(47):e31691. PubMed ID: 36451471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.